Name

Dosage Adult Dose Form(s) Nucleoside reverse transcriptase inhibitors (NRTIs) Abacavir (Ziagen) 300-mg tablet; 600 mg PO q 20-mg/mL oral or solution 300 mg PO bi 'i anosine ((i e)) *2+-mg% 200mg% 2+0-mg% ,00-mg entericcoate ca#sule; *0-mg/mL sus#ension 1mtricitabine (1mtriva) 200-mg ca#sule; *0-mg/mL oral solution Lamivu ine (1#ivir)

Adverse Events

!"#ersensitivit" reaction (ma" inclu e $ever% ras&% nausea% vomiting% iarr&ea% malaise% s&ortness o$ breat&% coug&% #&ar"ngitis) -60 .g/ ,00 mg Peri#&eral neuro#at&"% #ancreatitis% PO q nausea% lactic aci osis 060 .g/ 2+0 mg PO q 2inimal to)icit"% &"#er#igmentation

3tavu ine (Zerit)

4eno$ovir ((irea ) Zalcitabine (!ivi )

200 mg PO q or 2,0 mg (2, mL) oral solution PO q *+0-mg% 300-mg 300 mg PO q tablet; or *0-mg/mL oral *+0 mg PO bi solution *+-mg% 20-mg% -60 .g/ ,0 mg 30-mg% ,0-mg PO bi ca#sule; *-mg/mL oral 060 .g/ 30 mg solution PO bi 300-mg tablet 300 mg PO q

2inimal to)icit"

Peri#&eral neuro#at&"% #ancreatitis% lactic aci osis% li#oatro#&"% &"#erli#i emia 5ausea% vomiting% iarr&ea% &ea ac&e% ast&enia% renal insu$$icienc" Peri#&eral neuro#at&"% #ancreatitis% lactic aci osis% stomatitis 5ausea% vomiting% &ea ac&e% ast&enia% anemia% neutro#enia

0637+-mg% 067+- 067+ mg PO ti mg tablet Zi ovu ine (8etrovir) 300-mg tablet% 300 mg PO bi *00-mg ca#sule; or *0-mg/mL oral 200 mg PO ti solution; *0-mg/mL intravenous solution Nonnucleoside reverse transcriptase inhibitors (NNRTIs) 'elavir ine (8escri#tor) *00-mg% 200-mg ,00 mg PO ti 8as&% &ea ac&e tablets 1$aviren9 (3ustiva) 600-mg tablet; 600 mg PO q 8as&% :53 (eg% somnolence% vivi 200-mg ca#sule reams% con$usion% visual &allucinations) 1travirine (;ntelence) *00 mg tablet 200 mg PO bi 8as&% nausea 5evira#ine ((iramune) 200-mg tablet; 200 mg PO 8as&% &e#atitis *0-mg/mL bi a

sus#ension Protease inhibitors (PIs) Ata9anavir (8e"ata9) *+0-mg% 200mg% 300-mg ca#sules

,00 mg PO q or 300 mg < ritonavir *00 mg PO q 'arunavir (Pre9ista) ,00-mg% 600-mg =00 mg q < tablets ritonavir *00 mg PO q b or 600 mg bi < ritonavir *00 mg PO bi >osam#renavir (Le)iva) 700-mg tablet; 700 mg bi < +0-mg/mL oral ritonavir *00 sus#ension mg PO bi or *,00 mg PO bi or *,00 mg < ritonavir *00200 mg PO q b ;n inavir (:ri)ivan) *00-mg% 200=00 mg PO q=& mg% 333-mg% =00 mg PO bi ,00-mg ca#sules < ritonavir *00200 mg PO bi Lo#inavir/ritonavir 200-mg/+0-mg ,00 mg/*00 mg (?aletra) tablet; PO bi or =0-mg/20-mg =00 mg/200 mg #er mL oral PO q b solution 5el$inavir ((irace#t) 2+0-mg% 62+-mg *2+0 mg PO tablets bi or 7+0 mg PO ti (5el$inavir cannot be booste 6) 8itonavir (5orvir) *00-mg so$t @oosting ose gelatin ca#sule $or ot&er =0-mg/mL oral #rotease solution in&ibitors/ *00,00 mg/ (re$er to ot&er #rotease in&ibitors $or s#eci$ic ose) 5onboosting ose (8itonavir use as sole #rotease in&ibitor)/ 600

;n irect &"#erbilirubinemia% #rolonge P8 interval% &"#ergl"cemia 8as&% nausea% iarr&ea% &"#erli#i emia% &"#ergl"cemia

8as&% nausea% vomiting% iarr&ea% &"#erli#i emia% &"#ergl"cemia

5e#&rolit&iasis% nausea% in irect &"#erbilirubinemia% &"#erli#i emia% &"#ergl"cemia 5ausea% vomiting% iarr&ea% ast&enia% &"#erli#i emia% &"#ergl"cemia 'iarr&ea% &"#erli#i emia% &"#ergl"cemia

5ausea% vomiting% iarr&ea% ast&enia% &"#erli#i emia% oral #arest&esias% &"#ergl"cemia

3aquinavir (;nvirase)

+00-mg tablet; 200-mg &ar gelatin ca#sule

4i#ranavir (A#tivus)

2+0-mg so$t gelatin ca#sule

mg bi c *000 mg < ritonavir *00 mg PO bi Anbooste saquinavir is not recommen e +00 mg < ritonavir 200 mg PO bi Anbooste ti#ranavir is not recommen e ,00 mg PO bi

5ausea% iarr&ea% &ea ac&e% &"#erli#i emia% &"#ergl"cemia

!e#atoto)icit"% ras&% &"#erli#i emia% &"#ergl"cemia% intracranial &emorr&age (rare cases re#orte )

Integrase inhibitor (II) 8altegravir (;sentress) ,00-mg tablet

5ausea% iarr&ea% &ea ac&e% :? elevations% m"o#at&"/r&ab om"ol"sis (rare)

Chemo ine receptor antagonist (CCR! antagonist) 2araviroc (3el9entr") *+0-mg% 300-mg 300 mg PO bi :onsti#ation% i99iness% in$ection% tablets *+0 mg PO bi ras& (:BP3A, in&ibitors C in ucers) 600 mg PO bi (:BP3A, in ucers) Fusion inhibitor (FI) 1n$uvirti e (>u9eon) D0-mg/mL D0 mg 3: bi ;nFection-site reactions (eg% #ain% #oE er $or er"t&ema% in uration% no ules) inFection Combination "ormulations 1#9icom - Abacavir (600 mg) < lamivu ine (300 mg) q 4ri9ivir - Abacavir (300 mg) < lamivu ine (*+0 mg) < 9i ovu ine (300 mg) bi 4ruva a - 4eno$ovir (300 mg) < emtricitabine (200 mg) q Atri#la - 4eno$ovir (300 mg) < emtricitabine (200 mg) < e$aviren9 (600 mg) q :ombivir - Zi ovu ine (300 mg) < lamivu ine (*+0 mg) bi Name Dosage Adult Dose Adverse Events Form(s) Nucleoside reverse transcriptase inhibitors (NRTIs) Abacavir (Ziagen) 300-mg tablet; 600 mg PO q !"#ersensitivit" reaction (ma" 20-mg/mL oral or inclu e $ever% ras&% nausea% solution 300 mg PO bi vomiting% iarr&ea% malaise% s&ortness o$ breat&% coug&% #&ar"ngitis) 'i anosine ((i e)) *2+-mg% 200-60 .g/ ,00 mg Peri#&eral neuro#at&"% #ancreatitis% mg% 2+0-mg% PO q nausea% lactic aci osis ,00-mg entericcoate ca#sule; 060 .g/ 2+0 mg 3

*0-mg/mL sus#ension 1mtricitabine (1mtriva) 200-mg ca#sule; *0-mg/mL oral solution Lamivu ine (1#ivir)

PO q 2inimal to)icit"% &"#er#igmentation

3tavu ine (Zerit)

4eno$ovir ((irea ) Zalcitabine (!ivi )

200 mg PO q or 2,0 mg (2, mL) oral solution PO q *+0-mg% 300-mg 300 mg PO q tablet; or *0-mg/mL oral *+0 mg PO bi solution *+-mg% 20-mg% -60 .g/ ,0 mg 30-mg% ,0-mg PO bi ca#sule; *-mg/mL oral 060 .g/ 30 mg solution PO bi 300-mg tablet 300 mg PO q

2inimal to)icit"

Peri#&eral neuro#at&"% #ancreatitis% lactic aci osis% li#oatro#&"% &"#erli#i emia 5ausea% vomiting% iarr&ea% &ea ac&e% ast&enia% renal insu$$icienc" Peri#&eral neuro#at&"% #ancreatitis% lactic aci osis% stomatitis 5ausea% vomiting% &ea ac&e% ast&enia% anemia% neutro#enia

0637+-mg% 067+- 067+ mg PO ti mg tablet Zi ovu ine (8etrovir) 300-mg tablet% 300 mg PO bi *00-mg ca#sule; or *0-mg/mL oral 200 mg PO ti solution; *0-mg/mL intravenous solution Nonnucleoside reverse transcriptase inhibitors (NNRTIs) 'elavir ine (8escri#tor) *00-mg% 200-mg ,00 mg PO ti 8as&% &ea ac&e tablets 1$aviren9 (3ustiva) 600-mg tablet; 600 mg PO q 8as&% :53 (eg% somnolence% vivi 200-mg ca#sule reams% con$usion% visual &allucinations) 1travirine (;ntelence) *00 mg tablet 200 mg PO bi 8as&% nausea 5evira#ine ((iramune) 200-mg tablet; 200 mg PO 8as&% &e#atitis a *0-mg/mL bi sus#ension Protease inhibitors (PIs) Ata9anavir (8e"ata9) *+0-mg% 200,00 mg PO q ;n irect &"#erbilirubinemia% mg% 300-mg or #rolonge P8 interval% ca#sules 300 mg < &"#ergl"cemia ritonavir *00 mg PO q 'arunavir (Pre9ista) ,00-mg% 600-mg =00 mg q < 8as&% nausea% iarr&ea% tablets ritonavir *00 &"#erli#i emia% &"#ergl"cemia mg PO q b or 600 mg bi < ritonavir *00

mg PO bi >osam#renavir (Le)iva) 700-mg tablet; 700 mg bi < +0-mg/mL oral ritonavir *00 sus#ension mg PO bi or *,00 mg PO bi or *,00 mg < ritonavir *00200 mg PO q b ;n inavir (:ri)ivan) *00-mg% 200=00 mg PO q=& mg% 333-mg% =00 mg PO bi ,00-mg ca#sules < ritonavir *00200 mg PO bi Lo#inavir/ritonavir 200-mg/+0-mg ,00 mg/*00 mg (?aletra) tablet; PO bi or =0-mg/20-mg =00 mg/200 mg #er mL oral PO q b solution 5el$inavir ((irace#t) 2+0-mg% 62+-mg *2+0 mg PO tablets bi or 7+0 mg PO ti (5el$inavir cannot be booste 6) 8itonavir (5orvir) *00-mg so$t @oosting ose gelatin ca#sule $or ot&er =0-mg/mL oral #rotease solution in&ibitors/ *00,00 mg/ (re$er to ot&er #rotease in&ibitors $or s#eci$ic ose) 5onboosting ose (8itonavir use as sole #rotease in&ibitor)/ 600 mg bi c 3aquinavir (;nvirase) +00-mg tablet; *000 mg < 200-mg &ar ritonavir *00 gelatin ca#sule mg PO bi Anbooste saquinavir is not recommen e 4i#ranavir (A#tivus) 2+0-mg so$t +00 mg < gelatin ca#sule ritonavir 200 mg PO bi Anbooste

8as&% nausea% vomiting% iarr&ea% &"#erli#i emia% &"#ergl"cemia

5e#&rolit&iasis% nausea% in irect &"#erbilirubinemia% &"#erli#i emia% &"#ergl"cemia 5ausea% vomiting% iarr&ea% ast&enia% &"#erli#i emia% &"#ergl"cemia 'iarr&ea% &"#erli#i emia% &"#ergl"cemia

5ausea% vomiting% iarr&ea% ast&enia% &"#erli#i emia% oral #arest&esias% &"#ergl"cemia

5ausea% iarr&ea% &ea ac&e% &"#erli#i emia% &"#ergl"cemia

!e#atoto)icit"% ras&% &"#erli#i emia% &"#ergl"cemia% intracranial &emorr&age (rare cases re#orte )

ti#ranavir is not recommen e Integrase inhibitor (II) 8altegravir (;sentress) ,00-mg tablet ,00 mg PO bi 5ausea% iarr&ea% &ea ac&e% :? elevations% m"o#at&"/r&ab om"ol"sis (rare)

Chemo ine receptor antagonist (CCR! antagonist) 2araviroc (3el9entr") *+0-mg% 300-mg 300 mg PO bi :onsti#ation% i99iness% in$ection% tablets *+0 mg PO bi ras& (:BP3A, in&ibitors C in ucers) 600 mg PO bi (:BP3A, in ucers) Fusion inhibitor (FI) 1n$uvirti e (>u9eon) D0-mg/mL D0 mg 3: bi ;nFection-site reactions (eg% #ain% #oE er $or er"t&ema% in uration% no ules) inFection Combination "ormulations 1#9icom - Abacavir (600 mg) < lamivu ine (300 mg) q 4ri9ivir - Abacavir (300 mg) < lamivu ine (*+0 mg) < 9i ovu ine (300 mg) bi 4ruva a - 4eno$ovir (300 mg) < emtricitabine (200 mg) q Atri#la - 4eno$ovir (300 mg) < emtricitabine (200 mg) < e$aviren9 (600 mg) q :ombivir - Zi ovu ine (300 mg) < lamivu ine (*+0 mg) bi
G'osing gui es assume an absence o$ rug- rug interactions (e)ce#t ritonavir) an normal renal an &e#atic $unction6 a A minister 200 mg q $or 2 Eee.s% t&en increase to 200 mg bi 6 b A##rove onl" $or antiretroviral treatmentHnaIve #atients c 4itrate ose over *, a"s% beginning Eit& 300 mg bi on a"s *-2% ,00 mg bi on a"s 3-+% an +00 mg bi on a"s 6-*36 A##rove onl" $or antiretroviral treatmentHe)#erience #atients Eit& rug resistance